AstraZeneca (AZN) Competitors

AstraZeneca logo
$179.62 -2.65 (-1.45%)
As of 01:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AZN vs. AMGN, BIIB, MRNA, NVAX, and ABBV

Should you buy AstraZeneca stock or one of its competitors? AstraZeneca's main competitors and comparable companies include Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AstraZeneca compare to Amgen?

Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.2%. AstraZeneca pays an annual dividend of $2.17 per share and has a dividend yield of 1.2%. Amgen pays out 58.5% of its earnings in the form of a dividend. AstraZeneca pays out 30.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Amgen had 9 more articles in the media than AstraZeneca. MarketBeat recorded 29 mentions for Amgen and 20 mentions for AstraZeneca. Amgen's average media sentiment score of 0.75 beat AstraZeneca's score of 0.73 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
15 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
AstraZeneca
11 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive

Amgen currently has a consensus target price of $425.69, suggesting a potential downside of 7.04%. AstraZeneca has a consensus target price of $206.67, suggesting a potential upside of 13.41%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
3 Sell rating(s)
18 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.30
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84

Amgen has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

AstraZeneca has higher revenue and earnings than Amgen. AstraZeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B6.74$7.71B$17.2426.56
AstraZeneca$58.74B4.81$10.23B$7.0725.77

Amgen has a net margin of 24.14% compared to AstraZeneca's net margin of 17.68%. Amgen's return on equity of 114.99% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen24.14% 114.99% 13.47%
AstraZeneca 17.68%31.85%13.62%

Summary

Amgen beats AstraZeneca on 13 of the 20 factors compared between the two stocks.

How does AstraZeneca compare to Biogen?

AstraZeneca (NYSE:AZN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

AstraZeneca has a net margin of 17.68% compared to Biogen's net margin of 3.37%. AstraZeneca's return on equity of 31.85% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.68% 31.85% 13.62%
Biogen 3.37%9.38%5.69%

AstraZeneca has higher revenue and earnings than Biogen. AstraZeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca$58.74B4.81$10.23B$7.0725.77
Biogen$9.89B3.75$1.29B$2.34107.18

20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AstraZeneca presently has a consensus price target of $206.67, suggesting a potential upside of 13.41%. Biogen has a consensus price target of $254.41, suggesting a potential upside of 1.44%. Given AstraZeneca's stronger consensus rating and higher possible upside, equities research analysts clearly believe AstraZeneca is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67

In the previous week, Biogen had 16 more articles in the media than AstraZeneca. MarketBeat recorded 36 mentions for Biogen and 20 mentions for AstraZeneca. Biogen's average media sentiment score of 1.14 beat AstraZeneca's score of 0.73 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
11 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
18 Very Positive mention(s)
4 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

AstraZeneca has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Biogen has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Summary

AstraZeneca beats Biogen on 10 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to Moderna?

Moderna (NASDAQ:MRNA) and AstraZeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

AstraZeneca has a net margin of 17.68% compared to Moderna's net margin of -110.46%. AstraZeneca's return on equity of 31.85% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Moderna-110.46% -25.79% -15.85%
AstraZeneca 17.68%31.85%13.62%

AstraZeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$1.94B43.04-$2.82B-$7.10N/A
AstraZeneca$58.74B4.81$10.23B$7.0725.77

75.3% of Moderna shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Moderna had 20 more articles in the media than AstraZeneca. MarketBeat recorded 40 mentions for Moderna and 20 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.73 beat Moderna's score of 0.40 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moderna
8 Very Positive mention(s)
9 Positive mention(s)
12 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral
AstraZeneca
11 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive

Moderna currently has a consensus price target of $120.25, suggesting a potential downside of 41.85%. AstraZeneca has a consensus price target of $206.67, suggesting a potential upside of 13.41%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
4 Sell rating(s)
15 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.08
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84

Moderna has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

AstraZeneca beats Moderna on 10 of the 15 factors compared between the two stocks.

How does AstraZeneca compare to Novavax?

AstraZeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

AstraZeneca has a net margin of 17.68% compared to Novavax's net margin of -18.64%. AstraZeneca's return on equity of 31.85% beat Novavax's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.68% 31.85% 13.62%
Novavax -18.64%-14.82%-7.55%

AstraZeneca currently has a consensus target price of $206.67, suggesting a potential upside of 13.41%. Novavax has a consensus target price of $12.33, suggesting a potential upside of 54.94%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84
Novavax
3 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.20

20.4% of AstraZeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, AstraZeneca had 16 more articles in the media than Novavax. MarketBeat recorded 20 mentions for AstraZeneca and 4 mentions for Novavax. AstraZeneca's average media sentiment score of 0.73 beat Novavax's score of 0.56 indicating that AstraZeneca is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
11 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
Novavax
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AstraZeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca$58.74B4.81$10.23B$7.0725.77
Novavax$1.12B1.17$440.30M-$0.46N/A

AstraZeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Novavax has a beta of 2.65, suggesting that its stock price is 165% more volatile than the broader market.

Summary

AstraZeneca beats Novavax on 11 of the 15 factors compared between the two stocks.

How does AstraZeneca compare to AbbVie?

AstraZeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, AbbVie had 9 more articles in the media than AstraZeneca. MarketBeat recorded 29 mentions for AbbVie and 20 mentions for AstraZeneca. AbbVie's average media sentiment score of 1.05 beat AstraZeneca's score of 0.73 indicating that AbbVie is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
11 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
20 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

AstraZeneca has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

AstraZeneca has a net margin of 17.68% compared to AbbVie's net margin of 15.67%. AstraZeneca's return on equity of 31.85% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.68% 31.85% 13.62%
AbbVie 15.67%-450.55%16.50%

AstraZeneca has higher earnings, but lower revenue than AbbVie. AstraZeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca$58.74B4.81$10.23B$7.0725.77
AbbVie$61.16B8.45$4.23B$5.8150.33

20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AstraZeneca pays an annual dividend of $2.17 per share and has a dividend yield of 1.2%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.4%. AstraZeneca pays out 30.7% of its earnings in the form of a dividend. AbbVie pays out 119.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

AstraZeneca currently has a consensus price target of $206.67, indicating a potential upside of 13.41%. AbbVie has a consensus price target of $297.85, indicating a potential upside of 1.86%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than AbbVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84
AbbVie
0 Sell rating(s)
6 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

AbbVie beats AstraZeneca on 12 of the 20 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$278.67B$13.43B$7.66B$22.52B
Dividend Yield1.18%2.58%2.47%3.82%
P/E Ratio25.4128.8034.0029.21
Price / Sales4.747.318.443.28
Price / Cash14.2315.6321.0115.54
Price / Book5.385.434.483.67
Net Income$10.23B$2.88B$3.51B$1.07B
7 Day Performance-3.19%-4.63%-5.93%-4.09%
1 Month Performance8.71%-4.22%-4.31%-2.32%
1 Year Performance0.29%-6.83%-1.15%5.84%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
4.7656 of 5 stars
$179.62
-1.5%
$206.67
+15.1%
+1.9%$278.51B$58.74B25.4096,100
AMGN
Amgen
4.2842 of 5 stars
$465.67
-0.3%
$424.66
-8.8%
+34.0%$251.89B$38.90B27.0131,500
BIIB
Biogen
2.9289 of 5 stars
$253.40
+1.2%
$254.41
+0.4%
+52.3%$37.46B$10.30B108.297,500
MRNA
Moderna
1.4045 of 5 stars
$223.37
-3.4%
$113.75
-49.1%
+735.2%$90.38B$1.94BN/A4,700
NVAX
Novavax
1.9869 of 5 stars
$8.52
-2.7%
$12.33
+44.8%
+17.1%$1.41B$1.12BN/A749

Related Companies and Tools


This page (NYSE:AZN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners